Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 1.00 |
| ▸ | HTR2C | P28335 | 5/20 | 1.00 |
| ▸ | HTR2B | P41595 | 4/20 | 1.00 |
| ▸ | HTR1A | P08908 | 3/20 | 1.00 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.68 |
| ▸ | HTR1B | P28222 | 3/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.65 |
| ▸ | HTR1D | P28221 | 2/20 | 0.65 |
| ▸ | HTR6 | P50406 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | HTR7 | P34969 | 1/20 | 0.65 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.65 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9773007 | 1.00 | HTR2A (1.00) | HTR2AHTR2CHTR2BHTR1AGPR84 | |
| SCHEMBL29365282 | 1.00 | HTR2A (1.00) | HTR2AHTR2CHTR2BHTR1AGPR84 | |
| SCHEMBL9773017 | 1.00 | HTR2A (1.00) | HTR2AHTR2CHTR2BHTR1AGPR84 | |
| SCHEMBL19209536 | 0.90 | HTR2A (0.81) | HTR2AHTR2CHTR2BHTR1AHTR1B | |
| SCHEMBL25082193 | 0.88 | HTR2A (0.78) | HTR2AHTR2CHTR2BHTR1AGPR84 | |
| SCHEMBL29527215 | 0.86 | HTR2A (0.75) | HTR2AHTR2CHTR2BHTR1AGPR84 | |
| SCHEMBL20970870 | 0.86 | HTR2A (0.75) | HTR2AHTR2CHTR2BHTR1AGPR84 | |
| SCHEMBL23743302 | 0.86 | HTR2A (0.75) | HTR2AHTR2CHTR2BHTR1AGPR84 | |
| SCHEMBL30916155 | 0.86 | HTR2C (0.75) | HTR2AHTR2CHTR2BHTR1AHTR1B | |
| SCHEMBL29827214 | 0.86 | HTR2C (0.75) | HTR2AHTR2CHTR2BHTR1AHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 348 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4618981-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | Remedi, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| EP-4615585-A1 | METHODS OF USING TRAZODONE TO REVERSE THE EFFECTS OF 5-HT2A RECEPTOR AGONISTS | Gilgamesh Pharmaceuticals, Inc. (US) | 2025-09-17 | — | — | EP | claimed |
| US-20240390301-A1 | COMBINATIONS OF PERIPHERAL 5-HT2A RECEPTOR ANTAGONISTS AND CENTRAL 5-HT2A RECEPTOR AGONISTS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2024-11-28 | — | — | US | claimed |
| US-20240252535-A1 | CELLULAR COMPOSITION FOR TREATMENT OF DISEASES, DISORDERS OR CONDITIONS AND METHOD OF USE | YZTHERAPEUTIC PERFORMANCE LTD. (IL) | 2024-08-01 | — | — | US | claimed |
| WO-2024108195-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | REMEDI, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| WO-2024102458-A1 | METHODS OF USING TRAZODONE TO REVERSE THE EFFECTS OF 5-HT2A RECEPTOR AGONISTS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2024-05-16 | — | — | WO | claimed |
| EP-4208177-A1 | CELLULAR COMPOSITION FOR TREATMENT OF DISEASES, DISORDERS OR CONDITIONS AND METHOD OF USE | Yztherapeutic Performance Ltd. (IL) | 2023-07-12 | — | — | EP | claimed |
| WO-2023028086-A1 | COMBINATIONS OF PERIPHERAL 5-HT2A RECEPTOR ANTAGONISTS AND CENTRAL 5-HT2A RECEPTOR AGONISTS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-03-02 | — | — | WO | claimed |
| US-20230024804-A1 | PSILOCYBIN COMPOSITIONS | TURTLE BEAR HOLDINGS LLC (US) | 2023-01-26 | — | — | US | claimed |
| US-20220160737-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2022-05-26 | — | — | US | claimed |
| WO-2008112773-A2 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF NEURALLY MEDIATED HYPOTENSION | CHELSEA THERAPEUTICS, INC. (US) | 2008-09-18 | — | — | WO | claimed |
| US-20080221170-A1 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF FIBROMYALGIA | CHELSEA THERAPEUTICS, INC. | 2008-09-11 | — | — | US | claimed |
| EP-1948155-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING DROXIDOPA | Chelsea Therapeutics Inc. (US) | 2008-07-30 | — | — | EP | claimed |
| US-20080015181-A1 | Pharmaceutical Compositions Comprising Droxidopa | CHELSEA THERAPEUTICS, INC. | 2008-01-17 | — | — | US | claimed |
| WO-2008003028-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING DROXIDOPA | CHELSEA THERAPEUTICS, INC. (US) | 2008-01-03 | — | — | WO | claimed |
| EP-1112106-B1 | SEROTONERGIC 5HT2 AGONISTS FOR TREATING GLAUCOMA | ALCON MFG LTD (US) | 2005-11-23 | — | — | EP | claimed |
| US-6664286-B1 | Lower and control elevated intraocular pressure | ALCON MANUFACTURING, LTD. | 2003-12-16 | — | — | US | claimed |
| US-20030203912-A1 | Serotonergic 5HT2 agonists for treating glaucoma | MAY JESSE A (US) | 2003-10-30 | — | — | US | claimed |
| EP-1112106-A2 | SEROTONERGIC 5HT2 AGONISTS FOR TREATING GLAUCOMA | ALCON LABORATORIES, INC. (US) | 2001-07-04 | — | — | EP | claimed |
| WO-2000016761-A2 | SEROTONERGIC 5HT2 AGONISTS FOR TREATING GLAUCOMA | ALCON LABORATORIES, INC. (US) | 2000-03-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015181-A1 | Pharmaceutical Compositions Comprising Droxidopa | COMT, ACHE, MAOA | HTR2A 142/4885HTR2C 124/4885HTR2B 139/4885 |
| US-20240390301-A1 | COMBINATIONS OF PERIPHERAL 5-HT2A RECEPTOR ANTAGONISTS AND CENTRAL 5-HT2A RECEPTOR AGONISTS | HTR2A, HTR2C, HTR5A | HTR2A 1/4885HTR2C 2/4885HTR2B 5/4885 |
| US-20220160737-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | HTR2A 11/4885HTR2C 6/4885HTR2B 9/4885 |
| US-20230024804-A1 | PSILOCYBIN COMPOSITIONS | NES, PNMT, GAP43 | HTR2A 130/4885HTR2C 189/4885HTR2B 129/4885 |
| US-20080221170-A1 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF FIBROMYALGIA | HTR5A, FAAH, MTNR1B | HTR2A 25/4885HTR2C 38/4885HTR2B 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.